FlandersBio on Twitter

Follow us on Twitter

Archive for October 2016 - News

Archive for October 2016 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Promethera Biosciences Raises EUR 10 Million in a Series C-extension Financing to Advance its Broad Product Pipeline in Liver Diseases


Promethera Executes on Asian Expansion Strategy by Attracting Leading Institutional and Strategic Investors from Japan and South Korea read more

Aratana Therapeutics to Present at Two Upcoming Investor Conferences


Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, plans to present at the 2016 Credit Suisse Healthcare Conference on Tuesday, November 8 at 8:30 a.m. MT in Scottsdale, Arizona and at Stifel Healthcare Conference 2016 on Wednesday, November 16 at 8:45 a.m. ET in New York City. read more



Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative immunotherapies, today announced its cash & cash equivalents and liquid investments position and its highlights from the third quarter of 2016. read more

Galapagos: Robust progress in Q3 2016


Galapagos NV (Euronext & NASDAQ: GLPG) announces significant progress in R&D in the first nine months while reporting financial results in line with management guidance. These unaudited results of the first nine months are further detailed in an online Q3 2016 Report published on the Galapagos website, www.glpg.com. read more

TiGenix publishes transparency notifications pursuant to Article 14 of the Law of May 2, 2007


TiGenix NV (Euronext Brussels: TIG) announced today that it received two transparency notifications pursuant to Article 14, first paragraph of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions. read more

TiGenix provides update on proposed initial public offering in the United States


TiGenix NV (Euronext Brussels: TIG; the "Company"), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the filing of an amendment to its registration statement on Form F-1 with the U.S. Securities and Exchange Commission for the proposed initial public offering in the United States of its American Depositary Shares ("ADSs"), initially filed on December 22, 2015. The amendment includes a revised syndicate of underwriters for the proposed offering. The number and price of the ADSs to be offered will be determined if and when the initial public offering is launched. read more

argenx Reports Third Quarter 2016 Financial Results and Provides Business Update


argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided a business update and announced financial results for the third quarter ended 30 September 2016. read more

Galapagos to present progress in CF programs at NACFC 2016


Galapagos NV (Euronext & NASDAQ: GLPG) will present the following plenary presentations and posters at the North American Cystic Fibrosis Conference (NACFC) in Orlando this week: read more

MDxHealth Announces Positive Coverage Policy with Fourth-Largest Health Insurer in the United States


MDxHealth SA (Euronext: MDXH.BR) today announced that Health Care Services Corporation (HCSC) has issued coverage for patients meeting the eligibility criteria established under the positive medical policy on the ConfirmMDx® for Prostate Cancer test. read more

Study reveals which genes are critical to a plant’s response to drought


Because plants cannot relocate when resources become scarce, they need to efficiently regulate their growth by responding to environmental cues. Drought is the most important cause of reduced plant growth and crop yield, which makes insights into a plant’s drought response highly valuable to agriculture. A team of VIB and Ghent University researchers set out to shed more light on this vital topic through a research initiative led by Professor Dirk Inzé. The study provided major insights into how plants cope with water-limiting conditions, which can direct advanced breeding and genome engineering efforts to create high-performing, drought-tolerant crop plants. The findings are published in the leading academic journal The Plant Cell. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top